In Stock Cell Lines
The Piezo1 Knockout MC3T3 Cell Line is a CRISPR/Cas9-edited mouse pre-osteoblast cell line (MC3T3-E1 subclone 4) with targeted disruption of the mechanosensitive cation channel Piezo1. Loss of Piezo1 abolishes force-induced calcium influx and downstream activation of ERK/AKT pathways, impairing the osteogenic transcription factor Runx2 and reducing matrix mineralization. This model is ideal for investigating mechanotransduction, bone formation, and calcium signaling in bone cells. Key applications include calcium imaging, alkaline phosphatase and mineralization assays, mechanical stimulation studies, and drug screening for anabolic agents or treatments for osteoporosis and bone repair defects.
MARK2 Knockout A549 Polyclonal Cells
Cat. No. ARG11070
CERS5 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG17954
NHSL1 Knockout jurkat Polyclonal Cells
Cat. No. ARG13326
IRF3 Knockout HGC-27 Polyclonal Cells
Cat. No. ARG30053
CBR3 Knockout HGC-27 Polyclonal Cells
Cat. No. ARG42709
ALAD Knockout AGS Polyclonal Cells
Cat. No. ARG26522
The Piezo1 Knockout MC3T3 Cell Line is a CRISPR/Cas9-edited mouse osteoblast precursor line with targeted disruption of the Piezo1 gene. Derived from the MC3T3-E1 subclone 4 parental line, it provides a stable loss-of-function model for studying mechanotransduction and calcium-dependent signaling in pre-osteoblasts. Loss of Piezo1 eliminates the primary mechanosensitive channel, enabling dissection of force-induced pathways without endogenous channel interference. This knockout line is suitable for diverse in vitro assays examining bone cell biology and mechanosensing.
The parental MC3T3-E1 subclone 4 line, established from C57BL/6 mouse calvarial osteoblasts, is a well-characterized pre-osteoblast model that spontaneously differentiates into mineralizing osteoblasts. This cell line faithfully recapitulates osteoblast commitment, matrix deposition, and mineralization, serving as a standard system for bone formation research. Its inherent responsiveness to mechanical stimuli such as fluid shear and substrate strain makes it particularly valuable for investigating how physical forces regulate osteogenesis. The Piezo1 knockout variant retains this differentiation capacity while selectively removing mechanosensitive calcium entry.
Piezo1 encodes a mechanosensitive cation channel that converts membrane tension into calcium influx, triggering intracellular signaling cascades. In osteoblasts, Piezo1 is activated by mechanical stretch, shear stress, and agonists like Yoda1, and inhibited by GsMTx4 and Gd3+. Channel opening initiates calcium entry, activating calpain/calcineurin and downstream RhoA, ERK1/2, and AKT phosphorylation. These effectors converge on osteogenic transcription factors Runx2 and NFATc1, promoting BMP2 and ALP expression. Piezo1 cooperates with STOML3, TRPV4, integrins, and collagen I, linking matrix interactions to transcriptional programs controlling differentiation.
Piezo1 knockout in MC3T3 cells abolishes force-induced calcium influx and disrupts mechanical activation of ERK/AKT pathways, leading to downregulated Runx2 and impaired osteoblast differentiation and matrix mineralization. This phenotype underscores the channel??s essential role in converting biomechanical cues into anabolic bone cell responses. Consequently, the knockout line serves as an effective negative control for studying mechanotransduction-dependent osteogenesis and for evaluating the specificity of mechanical or pharmacological interventions targeting the Piezo1 axis.
Applications include calcium imaging to quantify mechanosensitive currents, ALP staining and Alizarin Red S assays for differentiation and mineralization, and molecular profiling via western blotting, RT-qPCR, or RNA-seq. The knockout line is compatible with mechanical stimulation platforms (stretch, shear) to examine signal transduction. It also supports drug screening for anabolic agents or mechanomimetics targeting bone diseases such as osteoporosis, fracture non-unions, or disuse osteopenia. For further information, please contact Ascent Research.